- Two categories: FDA-authorized prescription digital therapeutics (PursueCare RESET, RESET-O) and consumer apps (sobriety counters, urge logs, peer chat).
- Digital therapeutics are evidence-backed and prescribed; consumer apps are tracking and community tools, not treatment.
- Best uses: streak tracking, urge logging, peer support between sessions.
- Avoid apps with no privacy policy, apps that promise outcomes they cannot deliver, and any app pitched as a substitute for clinical care.
The app store has many apps that describe themselves as helpful for substance use, drinking reduction, or recovery. Some are clinical tools with regulatory clearance and studied efficacy. Most are consumer products that provide community, tracking, or education without a specific evidence base. A small number are better avoided.
Below is our current landscape review, organized by function. We do not have affiliate relationships with every product listed; see Affiliate Disclosure for what is and is not affiliate-linked.
The FDA-authorized digital therapeutics
These are the only substance-use apps with specific regulatory clearance and clinical trial evidence supporting efficacy claims.
RESET and RESET-O (PursueCare)
What it is: Prescription digital therapeutics authorized by the FDA. Originally developed by Pear Therapeutics, the assets were acquired by PursueCare in late 2023 and are now marketed as RESET (for substance use disorder: alcohol, cannabis, cocaine, stimulant) and RESET-O (for opioid use disorder as an adjunct to buprenorphine).
What it does: Delivers a 12-week CBT and Community Reinforcement Approach curriculum via structured interactive modules, combined with outpatient treatment and (for RESET-O) buprenorphine. PursueCare integrates both apps into a broader telehealth addiction-care platform including medical care, counseling, and pharmacy services.
What the evidence shows: Pivotal trials supported FDA clearance, showing statistically significant improvements in abstinence and treatment retention vs. treatment-as-usual without the app. A real-world analysis of 600+ SUD patients found 74% retained in treatment and 62% abstinent at 12 weeks. RESET-O showed a trend toward improved buprenorphine retention in a 24-week RCT (70.8% vs 51.9%), though the finding did not reach statistical significance.
Who it fits: Patients in active outpatient treatment whose program or clinician supports digital therapeutic integration. Prescription-only. Not available as a direct consumer download. Ask your treatment provider or visit pursuecare.com to find prescribing clinicians.
Other authorized digital therapeutics
The digital therapeutics category continues to evolve; newer products receive FDA authorization periodically. The defining characteristics of a legitimate digital therapeutic, as distinct from a consumer app, are: FDA authorization or equivalent regulatory status, clinical trial evidence, and prescription-based access through a clinician.
Drinking reduction apps
Reframe
What it is: A consumer app for people looking to reduce or quit drinking, built around a neuroscience-informed approach and structured daily content.
What it does: 160-day program of daily content (short articles, exercises, tracking tools), coaching, peer community, and goal-setting around moderation or abstinence.
What the evidence shows: Reframe has published outcome data from user cohorts showing reductions in drinking among engaged users. This is consistent with what structured drinking reduction interventions produce more broadly; the specific contribution of the app design is harder to isolate from user self-selection.
Who it fits: Non-severe alcohol users who are motivated to reduce or stop, are comfortable with an app-based structure, and do not have co-occurring conditions that require clinical attention.
Who it does not fit: Patients with moderate-to-severe alcohol use disorder, patients with a history of withdrawal symptoms or seizures, patients with co-occurring conditions. These patients need clinician-directed care, not an app. See Medications for Alcohol Use Disorder.
For a full review, see Reframe: In-Depth Review.
Sunnyside
What it is: A consumer drinking moderation app oriented to mindful drinking and reduction, with an integrated telehealth naltrexone option (Sunnyside Med) that moves it into medication-assisted territory.
What it does: Weekly drink-count goal-setting, tracking, personalized SMS check-ins, coaching, and community. Sunnyside Med adds a telehealth layer where members can consult a licensed prescriber and obtain a naltrexone prescription, integrating medication and behavioral support in one platform.
What the evidence shows: A 2024 third-party analysis published in Alcohol: Clinical & Experimental Research evaluated data from 46,000 Sunnyside members and found a 33% average reduction in weekly alcohol consumption over 12 weeks using the personalized SMS program. This is observational data, not an RCT, but the sample size and publication venue give it more weight than internal marketing figures alone.
Who it fits: Adults who want to reduce drinking without an abstinence requirement, who are comfortable with app-based tracking and coaching, and who do not have a clinical severity level requiring formal outpatient care. The Sunnyside Med addition makes it a reasonable first step for motivated individuals considering naltrexone who want a low-barrier entry point.
Who it does not fit: Anyone with moderate-to-severe AUD, withdrawal history, or significant co-occurring conditions. Those patients need clinician-directed care. See Medications for Alcohol Use Disorder.
Sobriety tracking and community apps
I Am Sober
What it is: A free/freemium app focused on sobriety tracking, milestone celebration, and community.
What it does: Counts days of sobriety, tracks time-of-day triggers, provides community features, offers motivational content.
What the evidence shows: No specific clinical trial. The approach is consistent with supportive recovery scaffolding, helpful adjunctively for many patients, not a substitute for clinical care.
Who it fits: Patients in outpatient treatment who find tracking and community helpful. Not a clinical tool.
Loosid
What it is: A social app oriented to sober lifestyle, dating, events, community.
What it does: Dating features, sober events listings, community content.
What the evidence shows: Not a clinical product. A lifestyle tool for people in recovery.
Who it fits: People in stable recovery looking for sober-friendly social and dating contexts.
Peer-support apps tied to mutual-help groups
AA meeting finders
Multiple apps provide AA meeting listings (in-person and online), sponsor connection, and step-work tools. These are utilities for people already working the AA program; they do not add clinical content and do not substitute for clinical care. The usefulness depends on how the person uses AA.
SMART Recovery
The SMART Recovery app provides access to SMART meetings (online and in-person), the 4-point program tools, and community resources. SMART Recovery itself has a modest but positive evidence base as a mutual-help approach and is often a good fit for patients who find the AA framework does not fit them.
Apps we are cautious about
A few patterns that warrant caution:
Apps that claim to replace treatment. Any app marketed as a substitute for clinician-directed care for moderate-to-severe substance use disorder is overstating its capacity. Digital tools are adjuncts, not replacements, for clinical care in meaningful-severity cases.
Apps with aggressive subscription models and ambiguous clinical claims. If the marketing emphasizes subscription conversion and makes efficacy claims without cited evidence, approach with skepticism.
Apps that sell data without disclosure. Recovery-related app data is sensitive. Check privacy policies. Some apps monetize user data to a greater extent than the user would likely endorse if asked directly.
Apps tied to lead-generation referrals. Some apps funnel users toward specific treatment programs via referral agreements. This is not inherently disqualifying, but it creates a financial conflict that is worth knowing about.
What apps cannot do
Worth saying explicitly. Apps cannot:
- Prescribe medications for opioid or alcohol use disorder. (Telehealth services that include apps can; the app itself cannot.)
- Replace clinical assessment for patients with significant substance use or co-occurring mental health concerns.
- Handle crises. If the user is in acute withdrawal, acute suicidality, or a medical emergency, the app is not the right tool. For crisis resources, see the Medical Disclaimer.
- Substitute for a therapeutic relationship with a trained clinician. For many patients, the relationship is the active ingredient in recovery; an app cannot replicate it.
Apps can:
- Provide structure and accountability between clinical sessions.
- Offer psychoeducation and skill reinforcement in-pocket.
- Connect users with peer community and reduce isolation.
- Support tracking of recovery-relevant variables (sleep, cravings, mood, use).
- Be a useful adjunct to a broader clinical plan.
The bottom line
For patients in active clinical care, a well-chosen app can be a useful adjunct, particularly for skill reinforcement, community, and tracking. For patients with significant substance use or co-occurring conditions, an app is not a substitute for clinical care and should not be treated as one. The FDA-authorized prescription digital therapeutics (PursueCare RESET and RESET-O) occupy a distinct category as regulated clinical tools that require a prescriber. Consumer apps like Sunnyside and Reframe have meaningful real-world outcome data and belong in the toolbox for motivated, lower-severity users. Tracking and community apps like I Am Sober and Loosid are best understood as adjunct support layers, not treatment. Know what tier you are working with before making a recommendation or choosing one for yourself.
What to read next
What to read next
Most people with substance use disorders can be treated effectively without residential rehab. Outpatient care, medications, and harm reduction are real options backed by clinical evidence. You do not have to make a permanent decision today. The next step can be small.